Cargando…
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756262/ https://www.ncbi.nlm.nih.gov/pubmed/33179323 http://dx.doi.org/10.1111/head.13997 |
_version_ | 1783626501587992576 |
---|---|
author | Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen Galic, Maja Seminerio, Michael J. Ramirez Campos, Verena Halker Singh, Rashmi B. Ailani, Jessica |
author_facet | Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen Galic, Maja Seminerio, Michael J. Ramirez Campos, Verena Halker Singh, Rashmi B. Ailani, Jessica |
author_sort | Lipton, Richard B. |
collection | PubMed |
description | BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to EM. METHODS: This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period and a 3‐month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675 mg at baseline) or monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of <15 headache days per month during the 3‐month treatment period or a reduction to <15 headache days per month in all 3 months of the treatment period. RESULTS: This analysis included data from 1088 CM patients (quarterly, n = 366; monthly, n = 365; placebo, n = 357). More fremanezumab‐treated patients with CM reverted to EM using either the monthly average number of headache days criteria for reversion (quarterly: 50.5% [185/366], P = .108; monthly: 53.7% [196/365], P = .012; vs placebo: 44.5% [159/357]) or the monthly headache day count at Months 1, 2, and 3 criteria for reversion (quarterly: 31.2% [114/366], P = .008; monthly: 33.7% [123/365], P = .001; vs placebo: 22.4% [80/357]). Patients with CM who reported previous topiramate or onabotulinumtoxinA use, concomitant preventive medication use, or medication overuse were less likely to revert to EM. CONCLUSIONS: Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache days over 3 months of treatment. |
format | Online Article Text |
id | pubmed-7756262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77562622020-12-28 Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen Galic, Maja Seminerio, Michael J. Ramirez Campos, Verena Halker Singh, Rashmi B. Ailani, Jessica Headache Research Submissions BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to EM. METHODS: This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period and a 3‐month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675 mg at baseline) or monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of <15 headache days per month during the 3‐month treatment period or a reduction to <15 headache days per month in all 3 months of the treatment period. RESULTS: This analysis included data from 1088 CM patients (quarterly, n = 366; monthly, n = 365; placebo, n = 357). More fremanezumab‐treated patients with CM reverted to EM using either the monthly average number of headache days criteria for reversion (quarterly: 50.5% [185/366], P = .108; monthly: 53.7% [196/365], P = .012; vs placebo: 44.5% [159/357]) or the monthly headache day count at Months 1, 2, and 3 criteria for reversion (quarterly: 31.2% [114/366], P = .008; monthly: 33.7% [123/365], P = .001; vs placebo: 22.4% [80/357]). Patients with CM who reported previous topiramate or onabotulinumtoxinA use, concomitant preventive medication use, or medication overuse were less likely to revert to EM. CONCLUSIONS: Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache days over 3 months of treatment. John Wiley and Sons Inc. 2020-11-11 2020 /pmc/articles/PMC7756262/ /pubmed/33179323 http://dx.doi.org/10.1111/head.13997 Text en © 2020 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Submissions Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen Galic, Maja Seminerio, Michael J. Ramirez Campos, Verena Halker Singh, Rashmi B. Ailani, Jessica Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title | Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title_full | Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title_fullStr | Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title_full_unstemmed | Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title_short | Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study |
title_sort | reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from halo cm study |
topic | Research Submissions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756262/ https://www.ncbi.nlm.nih.gov/pubmed/33179323 http://dx.doi.org/10.1111/head.13997 |
work_keys_str_mv | AT liptonrichardb reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT cohenjoshuam reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT bibeaukristen reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT galicmaja reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT semineriomichaelj reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT ramirezcamposverena reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT halkersinghrashmib reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy AT ailanijessica reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy |